Targeting oncogenic drivers is already a cornerstone of treatment for a subset of glioma patients, most notably those with Neurofibromatosis 1 (NF1) mutations, BRAF fusions and BRAFV600E mutated LGG and HGG (12–15). The gene discussed is NF1; the disease is glioma.